Atyr Pharma Inc
LIFE
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.55B
Close$
$3.42
91.3% downside
Current Fair Value
91.3% downsideOvervalued by 91.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.55 Billion |
|---|---|
| Enterprise Value | $2.55 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.14 |
| Beta | 4.21 |
| Outstanding Shares | 63,480,000 |
Return
| Return on Equity | -124.64% |
|---|---|
| Return on Assets | -87.08% |
| Return on Invested Capital | -109.29% |
Valuation & Multiples
| P/E Ratio | -15.36 |
|---|---|
| PEG | 32.54 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 13419.76 |
| Enterprise Value to EBIT | -39.93 |
| Enterprise Value to Net Income | -42 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.23 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$0.37
Average shareholder expectationRevenue Estimate
$117.31 M
Average shareholder expectationNext Earnings Call
Expected Date
November 2, 2026
EPS Estimate
$0.36
Average shareholder expectationRevenue Estimate
$163.38 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3384▲ 0.82% |
|---|---|
| Total Calls | 594,600▼ 12.05% |
| Total Puts | 201,227▼ 9.86% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 61.50%▼ 54.97% |
|---|---|
| Total Invested | $23.36M▼ 46.56% |
| Investors Holding | 99▼ 21.00% |
ESG Score
No data
About Atyr Pharma Inc
80 employees
CEO: Sanjay Shukla atyr pharma (nasdaq: life) is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology, a newly discovered set of physiological ...